Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...

REPLIMUNE GROUP ($REPL) posted quarterly earnings results on Thursday, May 22nd. The company reported earnings of -$0.82 per share, missing estimates of -$0.77 by $0. ...

Short interest in Replimune Group Inc (NASDAQ:REPL) decreased during the last reporting period, falling from 15.27M to 14.76M. This put 35.19% of the company's publicly available shares short. Based ...

Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.

Access detailed historical stock prices, including daily closing prices, for REPL. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Replimune Group Inc. Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was ...